GenoMethods - Biotechnology, Bioinformatics & AI in Biology

Stanford gives first FDA-approved Orca-T cell therapy for blood cancer

Stanford Medicine has given the first commercial dose of Orca-T, a new cell therapy for blood cancer, after its FDA approval in June 2026. The treatment is designed to cut the risk of graft-versus-host disease and improve patient recovery.

By Elena MacLeod · October 7, 2026, 5:42 PM · 5 mins read

Biomanufacturing

SD Guthrie fires up enzymatic fat lines at Liverpool plant

By Vivian Lin

Drug Discovery

Argenx axes Sjögren's UNITY trial after futility call

By Vivian Lin

Clinical Trials & Evidence

Collaborative Trials Open Advanced Therapies to HIV Lymphoma Patients

By Elena MacLeod

Drug Discovery

Rosera advances NLRP3 inhibitor ravnoflast to Phase 3 in cardiovascular disease

By Elena MacLeod

IN-DEPTH REPORTING

Biotechnology News & Analysis

Caribou Biosciences pulls out of major cancer trials after funding collapse

Caribou Biosciences, co-founded by Nobel laureate Jennifer Doudna, is shutting down its lymphoma and myeloma cell therapy programs and weighing a sale after failing to land new investment.

By Adrian Cole · October 7, 2026, 5:06 PM

Biotech Companies & Pipelines

Ofichem buys Kinentia Biosciences, plants US manufacturing flag

October 8, 2026, 10:46 AM

AI in Biology

Texas AI project hunts unseen triggers of eye disease

October 8, 2026, 8:34 AM

BIOTECHNOLOGY NEWS & ANALYSIS >

Translational Research

CAR T and bispecific antibody trials open doors for people with HIV and lymphoma

For the first time, people with HIV are being enrolled in CAR T and bispecific antibody trials for relapsed or refractory lymphoma. Early results are challenging old rules and showing these patients can safely join advanced studies.

By Elena MacLeod · October 6, 2026, 6:40 AM

Clinical Trials & Evidence

Diagnostics & Precision Medicine

GE HealthCare to buy Sofie Biosciences for $945 million in radiopharma push

October 5, 2026, 11:47 PM

Translational Research

Mount Sinai brings real time EHR-to-EDC automation to every clinical trial

October 5, 2026, 11:03 PM

Biotechnology, Decoded

GenoMethods explains biotechnology from method to medicine to market, connecting scientific evidence, clinical development, companies and the technologies shaping future health.

TOP STORIES

Stanford gives first FDA-approved Orca-T cell therapy for blood cancer

SD Guthrie fires up enzymatic fat lines at Liverpool plant

Argenx axes Sjögren's UNITY trial after futility call

Collaborative Trials Open Advanced Therapies to HIV Lymphoma Patients

Rosera advances NLRP3 inhibitor ravnoflast to Phase 3 in cardiovascular disease

IN-DEPTH REPORTING

Caribou Biosciences pulls out of major cancer trials after funding collapse

Ofichem buys Kinentia Biosciences, plants US manufacturing flag

Texas AI project hunts unseen triggers of eye disease

FEATURED STORIES

Whole exome sequencing opens new ground in pharmacogenomics

AI upends drug discovery and stirs debate over scientific credit

Genentech marks 50 years with documentary on biotech breakthroughs

Repligen closes $1.5 billion BioLife Solutions deal, pushing deeper into cell therapy

Generate Biomedicines doses first patient with AI-designed IL-18 armored CAR T for ovarian cancer

Caribou Biosciences pulls plug on lead CAR T cell therapies, launches strategic review

BIOTECHNOLOGY NEWS & ANALYSIS >

CAR T and bispecific antibody trials open doors for people with HIV and lymphoma

Global experts issue new rules for CAR T cell therapy in severe autoimmune disease

Lilly and Gate Bioscience expand partnership with new drug targets

CLINICAL TRIALS & EVIDENCE >

Pharma Giants Pour Billions Into Early China Biotech as US Tightens Rules

GE HealthCare to buy Sofie Biosciences for $945 million in radiopharma push

Mount Sinai brings real time EHR-to-EDC automation to every clinical trial

Biotechnology, Decoded